+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Psoriasis Therapeutics Market - Global Forecast 2026-2032- Product Image
Psoriasis Therapeutics Market - Global Forecast 2026-2032- Product Image
Sale

Psoriasis Therapeutics Market - Global Forecast 2026-2032

  • Report

  • 192 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4968898
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Psoriasis Therapeutics Market is projected to reach USD 29.10 Billion in 2026. It is expected to continue growing at a CAGR of 4.18%, reaching USD 37.26 Billion by 2032.

Psoriasis therapeutics address a chronic, immune-mediated inflammatory disease that affects skin, nails, joints, and quality of life. The World Health Organization recognizes psoriasis as a serious noncommunicable disease, with prevalence reported across studies from approximately 0.09% to 11.4%, reflecting differences in genetics, climate, diagnosis, and health-system reporting.

The treatment landscape spans topical corticosteroids and vitamin D analogs, phototherapy, conventional systemic agents such as methotrexate and cyclosporine, oral targeted therapies, and biologics that inhibit tumor necrosis factor, interleukin-12/23, interleukin-17, and interleukin-23 pathways. Growth in psoriasis therapeutics is being shaped by earlier specialist referral, treat-to-target care, comorbidity screening, biosimilar adoption, and demand for durable skin clearance with convenient dosing.

Transformative Shifts in the Psoriasis Treatment Landscape

The psoriasis therapeutics landscape is shifting from symptom control toward precision immunology and long-term disease control. Dermatology guidelines from organizations such as the American Academy of Dermatology, National Psoriasis Foundation, and European dermatology bodies support severity-based treatment selection, assessment of psoriatic arthritis risk, and escalation to systemic therapy when disease burden extends beyond body surface area alone.

Biologic innovation has raised expectations for Psoriasis Area and Severity Index improvement, while oral small molecules are expanding options for patients who prefer non-injectable therapy. At the same time, payer scrutiny, biosimilar competition, step-therapy policies, and real-world evidence requirements are transforming commercial strategy, making access, adherence, safety monitoring, and value demonstration central to therapeutic success.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly influencing psoriasis therapeutics across discovery, diagnosis, trial design, and patient support. In research settings, machine learning can help identify inflammatory signatures, stratify patients by likely response, and analyze imaging or genomic datasets that are too complex for manual review alone.

In clinical and commercial operations, AI-enabled tools support lesion assessment from digital images, remote monitoring, adherence prompts, pharmacovigilance signal detection, and real-world evidence generation. The cumulative impact is not a replacement for dermatologists; it is a more data-rich care pathway that can improve triage, personalize treatment sequencing, and reduce delays between inadequate response and therapy optimization.

Key Regional Insights

Asia-Pacific is gaining strategic relevance as China, India, Japan, South Korea, and Australia expand dermatology access, clinical research capacity, and reimbursement pathways for advanced therapies. The region combines large untreated or undertreated populations with rising diagnosis of immune-mediated diseases, although affordability and specialty-care availability remain uneven across urban and rural settings.

North America remains a highly developed psoriasis therapeutics environment, led by the United States and Canada, where biologics, oral targeted therapies, specialty pharmacies, and patient-support programs are well established. Europe is shaped by strong dermatology guideline adoption, health technology assessment, national reimbursement review, and biosimilar utilization, while the European Union supports harmonized regulatory standards and post-marketing safety expectations.

Latin America, led by Brazil and Mexico, shows demand for accessible systemic and biologic therapy as public and private systems improve specialty coverage. The Middle East, particularly Gulf markets, is supported by investment in specialty care and biologic access, while Africa remains more constrained by diagnosis gaps, out-of-pocket costs, specialist shortages, and limited access to advanced immunology therapies.

Key Group Insights

ASEAN markets show rising demand for psoriasis diagnosis and systemic treatment as urban healthcare networks expand in countries such as Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines. Access varies widely across the group, making tiered pricing, physician education, teledermatology support, and public-private collaboration important for broader treatment penetration.

The GCC benefits from high healthcare investment, specialist hospital networks, and increasing adoption of biologic therapy, although formulary inclusion and national procurement policies influence uptake. The European Union provides a structured environment for centralized approvals, pharmacovigilance, clinical guideline alignment, and biosimilar competition, which supports clinical confidence while intensifying price negotiation.

BRICS countries combine large patient pools with heterogeneous reimbursement, local manufacturing priorities, and growing demand for cost-effective immunology care. G7 countries represent mature evidence-driven markets with strong regulatory oversight and demand for real-world outcomes, while NATO member markets overlap significantly with North American and European systems where supply-chain resilience, cybersecurity, and healthcare infrastructure reliability influence therapeutic continuity.

Key Country Insights

The United States is central to psoriasis therapeutics because of high biologic utilization, active specialty pharmacy channels, and robust clinical trial participation. Canada emphasizes evidence-based reimbursement and provincial access decisions, while Mexico and Brazil are expanding specialist care but continue to balance biologic access with public-budget constraints and uneven regional coverage.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine guideline-based dermatology care with strong payer assessment, biosimilar use, and registry-driven evidence generation. Russia presents demand for systemic treatment but faces access variability, reimbursement complexity, and supply-chain pressures that can affect continuity of advanced therapies.

China and India offer large patient populations and growing dermatology infrastructure, with affordability, local evidence generation, and expanding clinical research shaping adoption. Japan, South Korea, and Australia have advanced regulatory systems, high specialty-care standards, and increasing use of biologics and oral targeted agents, making them important reference markets across Asia-Pacific.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated evidence that links skin clearance, itch reduction, joint-symptom monitoring, safety, dosing convenience, and quality-of-life improvement. Competitive advantage increasingly depends on proving value across both randomized clinical trials and real-world care settings, including persistence, switching patterns, and patient-reported outcomes.

Organizations should also strengthen market access planning before launch, develop biosimilar-response strategies, invest in patient adherence programs, and build compliant AI-enabled tools for dermatology workflows. Partnerships with dermatology networks, payers, specialty pharmacies, and patient organizations can improve diagnosis, persistence, and equitable access.

Research Methodology

This executive summary is based on a structured review of validated sources, including dermatology treatment guidelines, regulatory pathways, peer-reviewed clinical evidence, public-health information, therapy-class safety information, and health-system access patterns. Emphasis was placed on evidence that is reproducible, clinically relevant, and aligned with psoriasis therapeutic decision-making.

The analysis evaluates therapies by mechanism of action, route of administration, clinical utility, safety considerations, reimbursement environment, regional access, and technology impact. Insights are triangulated across clinical, commercial, regulatory, and patient-care dimensions to support strategic planning in the psoriasis therapeutics landscape without relying on market sizing, market share, or forecasting.

Conclusion

Psoriasis therapeutics are entering a more precise, evidence-intensive era defined by immunology innovation, payer accountability, digital health integration, and the rising importance of real-world outcomes. Biologics and oral targeted therapies have changed expectations for disease control, but access, affordability, adherence, and treatment sequencing remain decisive issues.

Organizations that combine strong clinical differentiation with regional access strategy, AI-enabled evidence generation, and patient-centered support will be best positioned to compete. The next phase of psoriasis care will reward therapies and services that deliver durable clearance, safety confidence, convenience, and measurable value across diverse healthcare systems.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Psoriasis Therapeutics Market, by Therapeutic Class
7.1. Introduction
7.2. Biologics
7.3. Phototherapy
7.3.1. Excimer Laser
7.3.2. Narrowband Uvb
7.3.3. Puva
7.4. Small Molecules
7.4.1. JAK Inhibitors
7.4.2. PDE4 Inhibitors
7.5. Topicals
7.5.1. Calcineurin Inhibitors
7.5.2. Corticosteroids
7.5.3. Vitamin D Analogues
8. Psoriasis Therapeutics Market, by Route Of Administration
8.1. Introduction
8.2. Injectable
8.2.1. Auto-Injector
8.2.2. Pre-Filled Syringe
8.2.3. Vial
8.3. Oral
8.3.1. Capsule
8.3.2. Tablet
8.4. Topical
8.4.1. Cream
8.4.2. Gel
8.4.3. Ointment
9. Psoriasis Therapeutics Market, by Disease Severity
9.1. Introduction
9.2. Mild
9.3. Moderate
9.4. Severe
10. Psoriasis Therapeutics Market, by Clinical Presentation
10.1. Introduction
10.2. Plaque Psoriasis
10.3. Guttate Psoriasis
10.4. Inverse Psoriasis
10.5. Pustular Psoriasis
10.6. Erythrodermic Psoriasis
11. Psoriasis Therapeutics Market, by Therapy Regimen
11.1. Introduction
11.2. Monotherapy
11.3. Combination Therapy
12. Psoriasis Therapeutics Market, by Patient Age Group
12.1. Introduction
12.2. Adult
12.3. Pediatric
12.4. Geriatric
13. Psoriasis Therapeutics Market, by End User
13.1. Introduction
13.2. Clinics
13.3. Dermatology Centers
13.4. Hospitals
14. Psoriasis Therapeutics Market, by Region
14.1. Asia-Pacific
14.2. North America
14.3. Latin America
14.4. Europe
14.5. Middle East
14.6. Africa
15. Psoriasis Therapeutics Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Psoriasis Therapeutics Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. Competitive Landscape
17.1. Market Share Analysis, 2025
17.2. FPNV Positioning Matrix, 2025
17.3. Market Concentration Analysis, 2025
17.3.1. Concentration Ratio (CR)
17.3.2. Herfindahl Hirschman Index (HHI)
17.4. Recent Developments & Impact Analysis, 2025
17.5. Product Portfolio Analysis, 2025
17.6. Benchmarking Analysis, 2025
18. Company Profiles
18.1. AbbVie Inc.
18.2. Almirall S.A.
18.3. Amgen Inc.
18.4. Arcutis Biotherapeutics Inc.
18.5. AstraZeneca PLC
18.6. Aurobindo Pharma Ltd.
18.7. Biogen Inc.
18.8. Boehringer Ingelheim International GmbH
18.9. Bristol Myers Squibb Company
18.10. Celltrion Inc.
18.11. Dermavant Sciences Ltd.
18.12. Dr. Reddy's Laboratories Ltd.
18.13. Eli Lilly and Company
18.14. Fresenius Kabi AG
18.15. Glenmark Pharmaceuticals Ltd.
18.16. Incyte Corporation
18.17. Intas Pharmaceuticals Ltd.
18.18. Johnson & Johnson Services, Inc.
18.19. LEO Pharma A/S
18.20. Merck & Co. Inc.
18.21. Novartis AG
18.22. Pfizer Inc.
18.23. Sandoz Group AG
18.24. STADA Arzneimittel AG
18.25. Sun Pharmaceutical Industries Ltd.
18.26. Takeda Pharmaceutical Company Limited
18.27. UCB S.A.
18.28. Zydus Lifesciences Ltd.
List of Figures
FIGURE 1. GLOBAL PSORIASIS THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL PSORIASIS THERAPEUTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL PSORIASIS THERAPEUTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL PSORIASIS THERAPEUTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2032 (%)
FIGURE 7. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICAL PRESENTATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICAL PRESENTATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPY REGIMEN, 2025 VS 2032 (%)
FIGURE 15. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPY REGIMEN, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
FIGURE 17. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 19. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 23. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 25. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL PSORIASIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 27. GLOBAL PSORIASIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL PSORIASIS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL PHOTOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL PHOTOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL PHOTOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL EXCIMER LASER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL EXCIMER LASER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL EXCIMER LASER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL NARROWBAND UVB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL NARROWBAND UVB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL NARROWBAND UVB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL PUVA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL PUVA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL PUVA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL SMALL MOLECULES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL SMALL MOLECULES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL SMALL MOLECULES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL JAK INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL JAK INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL JAK INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL PDE4 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL PDE4 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL PDE4 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL TOPICALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL TOPICALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL TOPICALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL CALCINEURIN INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL CALCINEURIN INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL CALCINEURIN INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL VITAMIN D ANALOGUES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL VITAMIN D ANALOGUES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL VITAMIN D ANALOGUES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL AUTO-INJECTOR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL AUTO-INJECTOR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL AUTO-INJECTOR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL PRE-FILLED SYRINGE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL PRE-FILLED SYRINGE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL PRE-FILLED SYRINGE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL VIAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL VIAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL VIAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL CAPSULE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL CAPSULE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL CAPSULE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL TABLET MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL TABLET MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL TABLET MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL CREAM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL CREAM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL CREAM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL GEL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL GEL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL GEL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL OINTMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL OINTMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL OINTMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL MILD MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL MILD MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL MILD MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL MODERATE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL MODERATE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL MODERATE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL SEVERE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL SEVERE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL SEVERE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICAL PRESENTATION, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL PLAQUE PSORIASIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL PLAQUE PSORIASIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL PLAQUE PSORIASIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL GUTTATE PSORIASIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL GUTTATE PSORIASIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL GUTTATE PSORIASIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL INVERSE PSORIASIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL INVERSE PSORIASIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL INVERSE PSORIASIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL PUSTULAR PSORIASIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL PUSTULAR PSORIASIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL PUSTULAR PSORIASIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL ERYTHRODERMIC PSORIASIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL ERYTHRODERMIC PSORIASIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL ERYTHRODERMIC PSORIASIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPY REGIMEN, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL MONOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL MONOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL MONOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL COMBINATION THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL COMBINATION THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL ADULT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL ADULT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL DERMATOLOGY CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL DERMATOLOGY CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL DERMATOLOGY CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 128. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 129. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 130. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2017-2032 (USD MILLION)
TABLE 131. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2017-2032 (USD MILLION)
TABLE 132. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2017-2032 (USD MILLION)
TABLE 133. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 134. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 135. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICAL PRESENTATION, 2017-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPY REGIMEN, 2017-2032 (USD MILLION)
TABLE 140. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 141. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 142. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 143. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 144. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2017-2032 (USD MILLION)
TABLE 145. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2017-2032 (USD MILLION)
TABLE 146. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2017-2032 (USD MILLION)
TABLE 147. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 148. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 149. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 150. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 151. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 152. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICAL PRESENTATION, 2017-2032 (USD MILLION)
TABLE 153. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPY REGIMEN, 2017-2032 (USD MILLION)
TABLE 154. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 155. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 156. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 157. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 158. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2017-2032 (USD MILLION)
TABLE 159. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2017-2032 (USD MILLION)
TABLE 160. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2017-2032 (USD MILLION)
TABLE 161. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 162. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 163. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 164. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 165. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 166. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICAL PRESENTATION, 2017-2032 (USD MILLION)
TABLE 167. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPY REGIMEN, 2017-2032 (USD MILLION)
TABLE 168. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 169. LATIN AMERICA PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 170. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 171. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 172. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2017-2032 (USD MILLION)
TABLE 173. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2017-2032 (USD MILLION)
TABLE 174. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2017-2032 (USD MILLION)
TABLE 175. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 176. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 177. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 178. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 179. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 180. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICAL PRESENTATION, 2017-2032 (USD MILLION)
TABLE 181. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPY REGIMEN, 2017-2032 (USD MILLION)
TABLE 182. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 183. EUROPE PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 184. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 185. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 186. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2017-2032 (USD MILLION)
TABLE 187. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2017-2032 (USD MILLION)
TABLE 188. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2017-2032 (USD MILLION)
TABLE 189. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 190. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 191. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 192. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 193. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 194. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICAL PRESENTATION, 2017-2032 (USD MILLION)
TABLE 195. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPY REGIMEN, 2017-2032 (USD MILLION)
TABLE 196. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 197. MIDDLE EAST PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 198. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 199. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 200. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2017-2032 (USD MILLION)
TABLE 201. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2017-2032 (USD MILLION)
TABLE 202. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2017-2032 (USD MILLION)
TABLE 203. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 204. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 205. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 206. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 207. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 208. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICAL PRESENTATION, 2017-2032 (USD MILLION)
TABLE 209. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPY REGIMEN, 2017-2032 (USD MILLION)
TABLE 210. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 211. AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 212. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 213. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 214. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 215. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2017-2032 (USD MILLION)
TABLE 216. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2017-2032 (USD MILLION)
TABLE 217. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2017-2032 (USD MILLION)
TABLE 218. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 219. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 220. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 221. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 222. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 223. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICAL PRESENTATION, 2017-2032 (USD MILLION)
TABLE 224. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPY REGIMEN, 2017-2032 (USD MILLION)
TABLE 225. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 226. ASEAN PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 227. GCC PSORIASIS THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 228. GCC PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 229. GCC PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2017-2032 (USD MILLION)
TABLE 230. GCC PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2017-2032 (USD MILLION)
TABLE 231. GCC PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2017-2032 (USD MILLION)
TABLE 232. GCC PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 233. GCC PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 234. GCC PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 235. GCC PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 236. GCC PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 237. GCC PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICAL PRESENTATION, 2017-2032 (USD MILLION)
TABLE 238. GCC PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPY REGIMEN, 2017-2032 (USD MILLION)
TABLE 239. GCC PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 240. GCC PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 241. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 242. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 243. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2017-2032 (USD MILLION)
TABLE 244. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2017-2032 (USD MILLION)
TABLE 245. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2017-2032 (USD MILLION)
TABLE 246. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 247. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 248. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 249. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 250. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 251. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICAL PRESENTATION, 2017-2032 (USD MILLION)
TABLE 252. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPY REGIMEN, 2017-2032 (USD MILLION)
TABLE 253. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 254. EUROPEAN UNION PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 255. BRICS PSORIASIS THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 256. BRICS PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 257. BRICS PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2017-2032 (USD MILLION)
TABLE 258. BRICS PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2017-2032 (USD MILLION)
TABLE 259. BRICS PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2017-2032 (USD MILLION)
TABLE 260. BRICS PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 261. BRICS PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 262. BRICS PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 263. BRICS PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 264. BRICS PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 265. BRICS PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICAL PRESENTATION, 2017-2032 (USD MILLION)
TABLE 266. BRICS PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPY REGIMEN, 2017-2032 (USD MILLION)
TABLE 267. BRICS PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 268. BRICS PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 269. G7 PSORIASIS THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 270. G7 PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 271. G7 PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2017-2032 (USD MILLION)
TABLE 272. G7 PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2017-2032 (USD MILLION)
TABLE 273. G7 PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2017-2032 (USD MILLION)
TABLE 274. G7 PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 275. G7 PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 276. G7 PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 277. G7 PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 278. G7 PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 279. G7 PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICAL PRESENTATION, 2017-2032 (USD MILLION)
TABLE 280. G7 PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPY REGIMEN, 2017-2032 (USD MILLION)
TABLE 281. G7 PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 282. G7 PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 283. NATO PSORIASIS THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 284. NATO PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 285. NATO PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2017-2032 (USD MILLION)
TABLE 286. NATO PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2017-2032 (USD MILLION)
TABLE 287. NATO PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2017-2032 (USD MILLION)
TABLE 288. NATO PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 289. NATO PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 290. NATO PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 291. NATO PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 292. NATO PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 293. NATO PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICAL PRESENTATION, 2017-2032 (USD MILLION)
TABLE 294. NATO PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPY REGIMEN, 2017-2032 (USD MILLION)
TABLE 295. NATO PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 296. NATO PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 297. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 298. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 299. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 300. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2017-2032 (USD MILLION)
TABLE 301. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2017-2032 (USD MILLION)
TABLE 302. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2017-2032 (USD MILLION)
TABLE 303. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 304. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 305. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 306. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 307. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 308. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICAL PRESENTATION, 2017-2032 (USD MILLION)
TABLE 309. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPY REGIMEN, 2017-2032 (USD MILLION)
TABLE 310. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 311. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 312. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 313. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 314. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2017-2032 (USD MILLION)
TABLE 315. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2017-2032 (USD MILLION)
TABLE 316. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2017-2032 (USD MILLION)
TABLE 317. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 318. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 319. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 320. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 321. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 322. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICAL PRESENTATION, 2017-2032 (USD MILLION)
TABLE 323. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPY REGIMEN, 2017-2032 (USD MILLION)
TABLE 324. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 325. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 326. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 327. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 328. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2017-2032 (USD MILLION)
TABLE 329. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2017-2032 (USD MILLION)
TABLE 330. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2017-2032 (USD MILLION)
TABLE 331. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 332. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 333. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 334. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 335. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 336. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICAL PRESENTATION, 2017-2032 (USD MILLION)
TABLE 337. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPY REGIMEN, 2017-2032 (USD MILLION)
TABLE 338. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 339. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 340. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 341. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 342. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2017-2032 (USD MILLION)
TABLE 343. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2017-2032 (USD MILLION)
TABLE 344. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2017-2032 (USD MILLION)
TABLE 345. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 346. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 347. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 348. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 349. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2017-2032 (USD MILLION)
TABLE 350. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICAL PRESENTATION, 2017-2032 (USD MILLION)
TABLE 351. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPY REGIMEN, 2017-2032 (USD MILLION)
TABLE 352. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 353. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 354. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 355. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 356. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2017-2032 (USD MILLION)
TABLE 357. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2017-2032 (USD MILLION)
TABLE 358. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2017-2032 (USD MILLION)
TABLE 359. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 360. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 361. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY

Companies Mentioned

  • AbbVie Inc.
  • Almirall S.A.
  • Amgen Inc.
  • Arcutis Biotherapeutics Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma Ltd.
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Celltrion Inc.
  • Dermavant Sciences Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Fresenius Kabi AG
  • Glenmark Pharmaceuticals Ltd.
  • Incyte Corporation
  • Intas Pharmaceuticals Ltd.
  • Johnson & Johnson Services, Inc.
  • LEO Pharma A/S
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sandoz Group AG
  • STADA Arzneimittel AG
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • UCB S.A.
  • Zydus Lifesciences Ltd.

Table Information

Report AttributeDetails
No. of Pages192
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 29.1 Billion
Forecasted Market Value ( USD ) by 2032 $ 37.26 Billion
Compound Annual Growth Rate4.1%
Regions CoveredGlobal
No. of Companies Mentioned28

Related Topics

Related Reports

Middle East Psoriasis Drugs Market Size, Share, Growth Drivers, Trends, Opportunities & Forecast 2025-2030 - Product Image

Middle East Psoriasis Drugs Market Size, Share, Growth Drivers, Trends, Opportunities & Forecast 2025-2030

  • Report
  • 90 Pages
  • Middle East
From
Psoriasis Drugs Market - Global Forecast 2026-2032 - Product Image

Psoriasis Drugs Market - Global Forecast 2026-2032

  • Report
  • 190 Pages
  • Global
From
IL-17 Inhibitors for Psoriasis Market - Global Forecast 2026-2032 - Product Image

IL-17 Inhibitors for Psoriasis Market - Global Forecast 2026-2032

  • Report
  • 189 Pages
  • Global
From
Chronic Plaque Psoriasis - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Chronic Plaque Psoriasis - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 200 Pages
  • Global
From
Psoriasis Treatment - Global Strategic Business Report - Product Image

Psoriasis Treatment - Global Strategic Business Report

  • Report
  • 566 Pages
  • Global
From

About the Psoriasis Drugs Market

The Psoriasis Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat psoriasis, a chronic skin condition. Psoriasis is characterized by red, scaly patches on the skin, and can cause itching, burning, and pain. Psoriasis drugs are designed to reduce inflammation, reduce the rate of skin cell growth, and reduce the severity of symptoms. The Psoriasis Drugs market is highly competitive, with many companies offering a variety of treatments. Some of the major players in the market include AbbVie, Amgen, Celgene, Janssen, and Novartis. These companies offer a range of treatments, including topical creams, oral medications, and biologic drugs. Other companies in the market include Sun Pharmaceuticals, Glenmark Pharmaceuticals, and Lupin Pharmaceuticals. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.